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1. Introduction 
Sixty-five years ago, the term telomere was introduced by Muller to describe the terminal 
elements of linear chromosomes (McClintock 1941). In 1985, Greider and Blackburn 
discovered the telomere synthesizing enzyme telomerase in Tetrahymena (Greider and 
Blackburn 1985). Three years after, the human telomeric DNA repeat sequence, TTAGGG, 
was identified (Moyzis, Buckingham et al. 1988). Since then, it has become apparent that 
several aspects of telomere biology are relevant to human cancer, offering potential 
opportunities for clinical intervention. In the work by Blackburn, Greider and Szostak, that 
was awarded the 2009 Nobel Prize in Physiology and Medicine (Zakian 2009), the structure 
of the chromosome ends was discovered to be specialized nucleoprotein structures that 
comprise the ‘‘end zone” of chromosomes, called telomeres. 
Several recent studies have highlighted the remarkable importance of telomeres in clinical 
medicine. These advances provide an opportunity to revisit some of the concepts and data 
that provide a link between telomeres and the diverse pathology that is now linked to 
telomere dysfunction. Here, we review the telomere and telomerase biology and the 
pharmacogenomic implications in human cancer, considering the importance of telomerase 
in tumor development.  
2. Telomeres and telomerase biology 
Telomeres are terminal protein-DNA complexes forming capping structures that function to 
stabilize chromosomal ends and prevent them from being recognized by the cell as DNA 
double strand breaks. Functional telomeres require sufficient numbers of telomeric DNA 
repeats, as well as the correct assembly of telomere associated protein complexes (Blasco 
and Hahn 2003). 
Telomeres consist of tandem repeats of a DNA sequence (TTAGGG in all vertebrates) bound 
by a six-protein complex, known as shelterin. Shelterin encompasses the Pot1-TPP1 
heterodimer, the telomere-binding proteins TRF1 and TRF2, and the interacting factors Rap1 
and Tin2 (de Lange 2005). Telomeric chromatin is also enriched in epigenetic marks that are 
characteristic of constitutive heterochromatin, such as histone tri-methylation and DNA 
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hypermethylation, which act as negative regulators of telomere length and telomere 
recombination (Blasco 2007). 
Telomere shortening below a certain threshold length or alterations in the functionality of 
the telomere-binding proteins can result in loss of telomeric protection, leading to end-to-
end chromosome fusions, cell cycle arrest and apoptosis. Telomeres also perform other 
functions, which include the transcriptional silencing of genes located close to the telomeres 
(subtelomeric silencing), as well as ensuring correct chromosome segregation during 
mitosis. Shortening of telomeres is associated with each round of cell division because of the 
inability of conventional DNA polymerases to replicate the ends of linear chromosomes, the 
so-called ‘end replication problem’. Telomerase is a cellular enzyme capable of 
compensating this progressive telomere attrition through de novo addition of TTAGGG 
repeats to the chromosome ends (Greider and Blackburn 1985). Telomerase encompasses a 
catalytic subunit with reverse transcriptase activity (Tert) and an RNA component (Terc) 
that acts as a template for DNA synthesis (Blasco 2007). 
Telomeres also solve the end protection problem. The DNA regions of the end zone are not 
blunt ended. Instead, they terminate in a long single-stranded run of the G-rich sequence on 
the 3’ strand, called the 3’ G-rich overhang. This long single-stranded tail of DNA is 
postulated to fold back onto itself to invade the duplex portion of telomeres, forming the t-
loop. The t-loop effectively sequesters the free ends of chromosomes, protecting them from 
being sensed as double strand breaks (Griffith, Comeau et al. 1999). 
High telomerase expression is a feature of pluripotent stem cells and early stages of 
embryonic development, although telomerase activity is also present in adult stem cell 
compartments (Blasco 2005). Telomerase activity in adult tissues, however, is not sufficient 
to prevent telomere shortening associated with ageing. 
The specificity of shelterin for telomeric DNA is through direct recognition of the TTAGGG 
sequence by three of its components. In particular, TRF1 and TRF2 bind to the double 
stranded region of telomeric DNA, while Pot1 binds to the TTAGGG repeats of the G-
overhang. TRF1 and TRF2 recruit the other four components of shelterin: Tin2 (a TRF1 and 
TRF2 interacting factor), Rap1, TPP1 and Pot1. These last two proteins form a heterodimer. 
Shelterin can form a stable complex in the absence of telomeric DNA (de Lange 2005). 
Mutations in the different components of telomerase (Tert, Terc and Dkc1), as well as in 
some shelterins (Tin2), have been linked to rare human genetic diseases, such as 
dyskeratosis congenita, aplastic anaemia and idiopathic pulmonary fibrosis. These diseases 
are associated with the presence of short/dysfunctional telomeres and they all exhibit a 
characteristic failure in the regenerative capacity of tissues and severe skin 
hyperpigmentation (Mitchell, Wood et al. 1999; Armanios, Chen et al. 2007).  
Adult stem cells reside at specific compartments within tissues, which are enriched in cells 
with the longest telomeres. In young or adult organisms with sufficient telomere reserve, 
adult stem cells efficiently repopulate tissues and repair lesions as needed. In old organisms, 
however, stem cell telomeres may be too short, and this could impair the mobilization of 
stem cells and the ability to repair tissues efficiently (Flores, Canela et al. 2008). 
When telomeres have shortened down to a critical length, they are recognized as DNA 
damage, activating a p53-mediated DNA damage signaling response that prevents the 
mobilization of the stem cells out of their niches. Decreased stem cell mobilization reduces 
the probability of accumulating abnormal cells in tissues, thus providing a mechanism for 
cancer protection. However, the ultimate consequence of impaired mobilization of the stem 
cells will be organ failure owing to tissue degeneration. By using mouse models over-
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expressing telomerase, some investigators showed that elevated TERT expression increases 
stem cell mobilization. Under these conditions of higher mobilization, the fitness of the 
tissues would be maintained for longer times, therefore increasing the lifespan. The 
probabilities of initiating a tumor, however, are also higher, especially if telomerase 
reactivation occurs in a context of mutations in tumor suppressor genes (Serrano and Blasco 
2007). 
3. Telomere shortening: Consequences 
Normally, cells respond to shortened or uncapped telomeres either by entering an 
irreversible cell cycle arrest, termed replicative senescence, or by undergoing apoptosis. 
Such responses involve both the Rb and p53 tumor suppressor pathways and likely evolved 
to prevent replication of mutation-prone cells harboring unstable chromosomes. If these 
checkpoints fail, chromosomal instability may occur and with it the potential for developing 
oncogenic mutations. If left unchecked, however, such instability will likely become lethal to 
the cell, thereby presenting an additional barrier to cell growth. Although some level of 
genetic instability is thought to be required for tumor initiation and progression, the vast 
majority of human cancers stabilizes their telomeres either by activating the enzyme 
telomerase or, in a minority of cases, by an alternative pathway, termed alternative 
lengthening of telomeres, or ALT, that seems to involve recombination (Reddel 2003). 
It would be advantageous in long-lived organisms for cells to be limited in the maximal 
number of cell divisions permitted, in order to ensure appropriate growth and DNA repair 
early in life, but not so many divisions that could lead to the early onset of diseases, such as 
cancer (Wright and Shay 2002). Therefore, selection for enhanced DNA repair and 
maintenance would be highly desirable during reproductive years, but this could be lost in 
later life (Kirkwood and Austad 2000). In our modern ‘protected environment’, humans are 
living on average twice as long and are dying of heart disease, cancer and 
neurodegenerative disorders. Thus, normal cells in the context of genotoxic injuries have 
innate and probably highly conserved defense mechanisms that initiate programs leading to 
growth arrest or apoptosis, perhaps in part as a mechanism to prevent cancer. 
3.1 Short telomeres activate DNA damage signals leading to cell cycle arrest in 
normal human cells 
Normal human somatic cells have a limited lifespan in vitro. This was first demonstrated in 
human fibroblasts by Hayflick and Moorhead in 1961 (Hayflick and Moorhead 1961). Since 
then, it has been demonstrated that cultured normal human fibroblasts go through finite 
numbers of population doublings. Toward the end of a cell’s lifespan, cell proliferation 
slows down and finally stops and the cell enters a state of irreversible growth arrest. The 
timing of growth arrest is determined by the number of population doublings the cells have 
undergone, not by the calendar time they have stayed in culture. In addition to fibroblasts, 
other somatic cells show replicative senescence, including epithelial cells, endothelial cells, 
lymphocytes, smooth muscle cells, and astrocytes, which serves as an intrinsic mechanism 
to prevent normal somatic cells from replicating indefinitely (Bierman 1978; Evans, Wyllie et 
al. 2003). Senescent human cells have increased p53 activity with the involvement of several 
DNA double strand break repair and checkpoint factors, such as ATM (Atadja, Wong et al. 
1995). These multiple DNA damage response factors are assembled at the short telomeres in 
senescent cells, indicating that dysfunctional short telomeres trigger the response (d'Adda di 
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Fagagna, Reaper et al. 2003; Zou, Sfeir et al. 2004). The sustained DNA damage response, 
signaling through p53, can induce both G1 and G2 phase arrest. Numerous studies have also 
demonstrated that human fibroblasts or epithelial cells undergoing natural replicative 
senescence have elevated protein levels of hypophosphorylated Rb, p16INK4a, as well as 
p21CIP1, or decreased hyper-phosphorylated Rb, compared with early and proliferating 
cells (Atadja, Wong et al. 1995; Beausejour, Krtolica et al. 2003). Telomere-mediated 
senescence is therefore induced by activation of the multiple DNA damage responses, which 
then leads to cell cycle arrest in normal human cells.  
Several lines of evidence have shown that replicative senescence also occurs in vivo and is 
thought to be associated with cellular aging. An inverse correlation between donor age and 
the number of population doublings at which human cells senesce has been demonstrated 
(Martin, Sprague et al. 1970). Moreover, comparisons between different species showed that 
cells from organisms with longer lifespan in vivo achieve more population doublings in vitro 
(Rohme 1981). Furthermore, cells from humans with premature aging syndromes have 
shorter lifespan in culture than those from age-matched controls (Smith and Pereira-Smith 
1996). These data suggest that there is a genetic basis that controls the cells’ replicative 
lifespan. However, although telomere-associated senescence is apparently an intrinsic 
barrier to cellular immortalization, which represents an early first step in the multi-stage 
process of cancer development, accumulation of senescent cells during aging in vivo seems 
to create a microenvironment that predisposes to cancer (Campisi 2005). Telomere 
shortening or dysfunction, therefore, presents a close association with cancer. 
3.2 Telomere dysfunction leads to genomic instability in checkpoint defective cells 
Broken chromosome ends tend to fuse with their sister chromatids or other broken 
chromosomes, leading to formation of anaphase bridges, cycles of chromosome breaks and 
further fusions during subsequent cell divisions (McClintock 1941). Telomere dysfunction 
initiates chromosomal instability through such breakage-fusion bridge (BFB) cycles. The p53 
and Rb/p16INK4a pathways are crucial for DNA damage responses, cell cycle regulation, as 
well as apoptosis, which are indispensable for maintaining genomic stability. Most cancers 
have alterations in either or both of these pathways. Inactivation of the p53 and 
p16INK4a/Rb pathways can be accomplished in vitro by expression of viral oncogenes, such 
as HPV (human papillomavirus) E6 and E7 or adenovirus E1B and E1A (Moran 1993; Moran 
1993) to stimulate the sustained inactivation of p53 and Rb genes, observed in cancers. Such 
alterations extend the lifespan and allow the cells to override cell cycle checkpoints and 
continue to proliferate. However, as telomeres continue to shorten with further cell 
divisions, the chromosome ends are no longer protected and become unstable. At this stage, 
the cells enter a mortality barrier, termed crisis (Wright and Shay 1992), which is 
characterized by wide-spread cell death and extensive chromosomal instability (Ducray, 
Pommier et al. 1999). However, a low percentage of cells may survive the crisis period by a 
mutation or an epigenetic event that activates a telomere maintenance mechanism. This may 
involve activation of telomerase, which elongates telomeres by synthesizing telomeric DNA 
and maintaining pre-existing telomeres, or an alternative telomere lengthening (ALT) 
mechanism, which involves copying of DNA sequences from telomere to telomere by means 
of homologous recombination. The resulting telomere preservation allows the cells to 
continue their long-term proliferation to become immortalized (Figure 1) (Dunham, 
Neumann et al. 2000). 
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Fig. 1. Telomeres shorten with cell proliferation when not balanced by telomere synthesis. In 
healthy somatic cells, critically short telomeres activate a checkpoint that induces either 
apoptosis or the proliferative arrest of replicative senescence. In the absence of checkpoint 
function, telomeres may become substrates for aberrant DNA repair. Occasionally, 
spontaneous activation of telomerase during the crisis phase of genomic instability stabilizes 
and allows maintenance of the rearranged genome, conferring indefinite renewal capacity. 
Critically short telomeres are hotspots for erroneous recombination. Whereas very few 
chromosome end-to-end fusions are observed in senescent normal human cells (Benn 1976; 
Zou, Sfeir et al. 2004), the frequencies of chromosome end-to-end fusions, reach a peak 
during crisis and decrease after this period due to telomere preservation (Ducray, Pommier 
et al. 1999). This is because the two centromeres are pulled in opposite directions during 
mitotic anaphase, forming a bridge between the daughter cells. The bridge can cause cell 
death independently of p53 and Rb genes, partly because the bridge compromises the 
integrity of cellular and nuclear membranes. The broken ends trigger DNA recombination 
by rejoining to other broken or unprotected chromosome ends. This can produce additional 
aberrations, such as structurally stable translocations and unstable dicentrics, which can 
undergo another round of BFB. Repeated cycles of sister-chromatid fusion-bridge breakage 
may, therefore, generate multiple copies of the same gene on the same chromosome in the 
same cell, while causing the loss of the genes in its sister cells after several rounds of cell 
divisions (Gisselsson, Jonson et al. 2001). In summary, regardless of how telomeres become 
disrupted, when telomeres become dysfunctional and can no longer protect the 
chromosome ends, they elicit a DNA damage response to activate the p53 and 
p16INK4a/Rb pathways, which prompt the cell to undergo irreversible cell cycle arrest (if 
both p53 and pRb checkpoints are intact) or p53-mediated apoptosis (if only the p53 
checkpoint is intact) (d'Adda di Fagagna, Reaper et al. 2003). In cells defective in both p53 
and p16INK4a/Rb pathways, excessive shortening of telomeres, coupled with the freedom 
to continue proliferation, promote aberrant fusions of unprotected chromosome ends and 
trigger massive chromosomal instability, increasing the risk of malignant transformation 
(Feldser, Hackett et al. 2003). Thus, telomere shortening can be both a barrier and a 
facilitator for cancer development, depending on the integrity of checkpoint response. 
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4. Role of telomere-mediated genomic instability in carcinogenesis 
Carcinogenesis is a multistep process, characterized by a stepwise accumulation of genetic 
and molecular abnormalities. These events generally follow exposure to carcinogens and 
result in the selection of clonal cells with uncontrolled growth capacities (Hanahan D 2000). 
Thus, cancer develops through a series of stepwise events, from preinvasive histological 
changes to invasive disease. The earliest events are mutations, deletions, or polysomy at the 
genomic level, but these do not systematically lead to changes in cell morphology or tissue 
structure. Current knowledge indicates that cancer progression from premalignancy to 
malignancy is slow and multiple mutations are required to reach a full metastatic potential 
(Schedin and Elias 2004). 
Tumor cells acquire the so-called hallmarks of cancer during this carcinogenic selection 
process (Hanahan D 2000). Cell immortality is one of the most prevalent of these major 
acquired features. Immortality involves the stabilization of telomere lengths, which is 
achieved by telomerase activation in about 80% of cases of human tumors. However, the 
specific changes in telomere length, telomeric proteins and telomerase expression that occur 
during the multistep carcinogenic process remain undetermined and thus represent a field 
of active research. 
One of the core concepts in cancer research is that genomic instability helps drive 
development of human cancer (Maser and DePinho 2002). Rapid evolution of genomic 
alterations in genetically unstable cells makes them advantageous in natural selection by 
acquiring new features. Of the two categories of genomic instability, microsatellite 
instability exists only in a small subset of solid tumors, whereas chromosomal instability is 
present in most cancers. Chromosomal instability includes numerical instability reflected by 
alterations in chromosome numbers, and structural instability, which is characterized by 
continuous generation of new structural chromosome aberrations. Regarding the role of 
chromosome aberrations in cancer development, it is well recognized that chromosome 
aberrations have oncogenic potential. First, chromosome translocations can result in the 
formation of fusion genes or deregulation of gene transcription at or near the translocation 
points, as demonstrated in most leukemia and many soft-tissue tumors. Second, gains or 
losses of chromosome elements or whole chromosomes can lead to large scale genomic 
imbalances or alterations in gene dosage in human cancers (Albertson, Collins et al. 2003). 
These abnormalities persist along with continued acquisition of additional abnormalities 
with tumor progression towards late stage malignancies. It is known that chromosomal 
instability is an important mechanism leading to genomic rearrangement and imbalances 
that provide a platform for continuous selection of aberrant cells for cellular immortalization 
and cancer development. The mouse model with the depletion of telomerase RNA 
component (mTerc) shows increased incidence of spontaneous malignancies in late 
generation animals (Rudolph, Chang et al. 1999; Maser and DePinho 2002). 
Extensive studies have shown that telomeres in normal human somatic cells shorten with 
cell divisions in vitro as well as in vivo. In cultured human fibroblasts, this progresses at a 
rate of 50-200 bp per population doubling (Harley, Futcher et al. 1990; Allsopp, Vaziri et al. 
1992). In vivo studies have also shown that the average telomere lengths in normal somatic 
cells shorten at an estimated rate of 15-40 bp per year and that telomere erosion declines 
with age (Hastie, Dempster et al. 1990). One major mechanism leading to telomere 
shortening is associated with the end-replication problem intrinsic to linear chromosomes. 
To date, numerous experiments have demonstrated that telomeric DNA is indeed 
progressively lost with cell divisions in most human somatic cells that lack telomerase 
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activity. In addition, some studies also suggest that oxidative stress contributes to telomere 
shortening. Under conditions of additional oxidative stress induced by hydrogen peroxide 
treatment, human cells show preferential accumulation of single-strand breaks within the 
telomeres. The effects of oxidative stress on telomere erosion has important significance in 
the study of telomere dynamics in aging and cancer, since numerous oxidants are produced 
in vivo due to normal metabolism and extracellular stresses and oxidative stress increases 
with the aging process in vivo (Saretzki and Von Zglinicki 2002; von Zglinicki 2002). 
Proof that telomeres shortening and cellular aging are causally related was demonstrated 
(Bodnar, Ouellette et al. 1998). The introduction of telomerase into normal telomerase silent 
cells was sufficient to bypass senescence, activate telomerase activity and lead to cell 
immortalization. It was further shown that ectopic expression of telomerase (TERT) in pre-
senescent cells or in cells between senescence and crisis could be immortalized with ectopic 
introduction of TERT, demonstrating that telomeres are mechanistically important in both 
senescence and crisis. In the absence of intact critical checkpoint pathways, genomic 
instability occurs when telomeres are short, leading to end-to-end fusions, anaphase 
bridges, the development of aneuploidy and eventually to telomerase reactivation. One 
possibility is that the re-expression or upregulation of telomerase in cancer reduces the 
ongoing chromosomal instability that occurs in cells in crisis to a level compatible with both 
viability and sufficient instability to generate mutational evolution of the malignancy. In 
summary, telomere shortening may be a common underlying cause of chromosomal 
rearrangements in cancer (Bodnar, Ouellette et al. 1998). In a recent study, DePinho and 
colleagues determined whether entrenched multi-system degeneration in adult mice with 
severe telomere dysfunction can be halted or possibly reversed by reactivation of 
endogenous telomerase activity. These authors engineered a knock-in allele encoding a 4-
hydroxytamoxifen (4-OHT)-inducible telomerase reverse transcriptase-oestrogen receptor 
(TERT-ER) under transcriptional control of the endogenous TERT promoter. Homozygous 
TERT-ER mice presented short dysfunctional telomeres and sustained increased DNA 
damage signalling and classical degenerative phenotypes upon successive generational 
matings and advancing age. Telomerase reactivation in such late generation TERT-ER mice 
extended telomeres, reduced DNA damage signalling and associated cellular checkpoint 
responses, allowing resumption of proliferation in quiescent cultures and eliminating 
degenerative phenotypes across multiple organs including testes, spleens and intestines. 
The authors demonstrated that telomere damage acts as a driver of age-associated organ 
decline and disease risk and that the marked reversal of systemic degenerative phenotypes 
in adult mice supports the development of regenerative strategies designed to restore 
telomere integrity (Jaskelioff, Muller et al. 2011). 
Since cancer cells have to bypass senescence and crisis, it is consistent to assume that the 
cancer cell that first became immortal by upregulating telomerase would have had short 
telomeres (Figure 2). For example, in most cases of preneoplasia, it has been shown that cells 
have very short telomeres. In prostate cancer for example, telomere shortening is detected in 
low grade prostatic intraepithelial neoplasia (PIN) lesions (Koeneman, Pan et al. 1998; 
Meeker, Hicks et al. 2002). This indicates that the tumor initiating cells are likely to originate 
from a subset of transient amplifying cells which may have critically shortened telomeres.  
Telomere length abnormalities are nearly universal in preinvasive stages of human 
epithelial carcinogenesis. Indeed, telomere shortening occurs in most cases of early stage 
bladder, cervix, colon, oesophagal and oral cavity cancer. Similar results were found for 
prostate cancer; the majority of high-grade PIN lesions (Prostatic intraepithelial neoplasia) 
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examined had much shorter telomeres than adjacent, apparently normal epithelial cells. This 
was also observed in fully invasive prostate carcinomas (Meeker, Hicks et al. 2002; Meeker, 
Hicks et al. 2004). Markedly or moderately shortened telomeres have also been found in 
lesions of ductal carcinoma in situ (Meeker and Argani 2004). Unlike normal breast 
epithelium, a moderate telomere shortening was observed in benign secretory cells in about 
half of histologically normal terminal duct lobular units. These findings clearly support a 
role for telomere shortening in pre-invasive stages, as well as in invasive cancer. Overall, 
these observations suggest that telomere length abnormality is one of the earliest and most 
frequently acquired genetic alterations involved in the multistep process of malignant 
transformation.  
 
 
Fig. 2. Schematic representation of telomere length associated with multistep carcinogenesis. 
As mentioned above, telomere shortening appears to be a signal for replication arrest in 
many cells. However, in some cells, rather than inducing cell cycle arrest, the substantial 
shortening of telomeres results in cycles of end-to-end fusions and BFB (Chin, de Solorzano 
et al. 2004; Lantuejoul, Soria et al. 2005). In most cells, damage-surveillance mechanisms 
detect genomic instability and induce cell death. Occasionally, however, one or a few cells 
escape this protective mechanism, leading to accumulation of multiple genomic and 
epigenomic aberrations and thus acquisition of additional cancer hallmark features (Chin, 
de Solorzano et al. 2004). 
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5. Heterogenity in telomere lengths - impact on cancer development and 
prognosis 
It is known that telomere length varies considerably among individuals. To date, the 
major conclusions on human telomere lengths include that there are large differences in 
telomere lengths between the arms of the same chromosomes, as well as between the 
same arms of homologous chromosomes in the cells of the same individual; different 
individuals have different profiles of telomere length heterogeneity, which seem to be 
largely inherited; and different tissues of the same individual have similar telomere 
length heterogeneity (Lansdorp, Verwoerd et al. 1996; Graakjaer, Bischoff et al. 2003; 
Nordfjall, Larefalk et al. 2005). 
There is growing evidence that TL (Telomere Length) carries information that may be of 
clinical importance for cancer patients. It is well established that TL is important for 
senescence in normal cells. Malignant cells in general have shorter telomeres than their 
normal counterparts and there seems to be a connection between telomere shortening, 
genetic aberrations and risk of transformation (Hackett and Greider 2002). The interest of 
investigating TL as a potential clinical biomarker in cancer has grown considerably in recent 
years (Ohyashiki, Sashida et al. 2002; Bisoffi, Heaphy et al. 2006).  
The vast majority of studies in the field have been performed on tumor samples, but there 
are also investigations on blood cell TL and its possible relation to cancer risk and prognosis. 
When tumor DNA is studied, TL reflects the cumulative result of a variety of tumor-
associated factors with impact on telomere homeostasis. TL in peripheral blood is often used 
as a surrogate for TL in other healthy tissues. The fact that TL in peripheral blood may carry 
clinical information for cancer patients has been indicated by a growing number of studies. 
One question to be solved, however, is whether altered blood TL can contribute to disease 
development, or whether the TL alterations arise as a consequence of the disease. The latter 
case would suggest that an altered blood TL is the result of unknown mechanisms 
associated with the presence of a malignant tumor in the body. Previous data indicate that 
blood TL may serve both as a marker for cancer risk and as an independent prognostic 
marker for survival. Thus, both tumor TL and TL in peripheral blood may carry information 
with important clinical implications. 
In hematological malignancies, there are convincing data suggesting that short telomeres in 
malignant hematopoietic cell populations indicate progressive disease and poor survival 
[reviewed in (Ohyashiki, Sashida et al. 2002; Bisoffi, Heaphy et al. 2006)]. 
A number of studies have reported that TL in solid tumors has potential to be used as a 
prognostic indicator. Several different tumor types have been investigated regarding tumor 
TL and clinical outcome. The majority of studies have found associations between altered 
tumor TL, i.e. attrition or elongation, and a poor outcome. Several studies have reported 
associations between reduced telomere content and poorer survival in both breast and 
prostate carcinomas. Similarly, in sarcoma, short TL was linked to genomic instability and 
poor survival (Bisoffi, Heaphy et al. 2006). A number of studies indicated that telomere 
alterations are associated with parameters of clinical outcome in patients with lung cancer 
(Shirotani, Hiyama et al. 1994; Hirashima, Komiya et al. 2000; Frias, Garcia-Aranda et al. 
2008). A study (Frias, Garcia-Aranda et al. 2008) indicated a significant poor clinical 
outcome in lung patients presenting telomere shortening, a finding that emerged as an 
independent prognostic marker in multivariate analysis. In other tumor types, such as 
prostate cancer, it has been suggested that reduced telomere content is associated with poor 
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clinical outcome and markers of disease progression. Thus, reduced telomere content values 
conferred a relative hazard of 5.02 compared with tumors with greater telomere content 
(Fordyce, Heaphy et al. 2005). Also, studies in breast cancer have shown that telomere 
attrition is associated with parameters of increased risk and poor outcome, with low 
telomere content conferring an adjusted relative hazard of 4.43 (Bisoffi, Heaphy et al. 2006; 
Fordyce, Heaphy et al. 2006).  
In contrast, long telomeres, or a high tumor to non-tumor TL ratio, have been coupled to 
tumors of more advanced stages and a worse prognosis in colorectal carcinoma, Barrett 
carcinoma and head and neck tumors (Patel, Parekh et al. 2002; Gertler, Rosenberg et al. 
2004; Garcia-Aranda, de Juan et al. 2006; Gertler, Doll et al. 2008). Although not entirely 
consistent, most studies have indicated that tumor TL alterations are associated with a 
worse clinical outcome. The type of alteration linked to a poorer survival (short vs. long TL) 
might depend on the tumor type. At the present time, the underlying mechanisms remain 
unclear. As for short TL and its association to a poorer outcome, it is logical to consider the 
relation between short TL and genomic instability.  
5.1 Blood telomere length as a potential predictor for cancer risk and prognosis 
There is a need for reliable, easily measurable biological markers for risk and prognosis 
assessment of malignancies. In recent years, a growing number of studies have focused on 
analyzing telomeres in peripheral blood cells in relation to cancer risk. Since blood is an 
easily accessible biological sample, blood TL is an interesting candidate as a biological 
marker. However, previous reports from this research area are not unambiguous. In renal, 
lung, bladder, head and neck and oesophagus carcinomas, short TL in peripheral blood 
have been associated with increased cancer risk (Wu, Amos et al. 2003; McGrath, Wong et al. 
2007; Risques, Vaughan et al. 2007; Jang, Choi et al. 2008). Similar data have been reported 
for malignant lymphoma (Widmann, Herrmann et al. 2007). Regarding breast cancer, a 
study in sister sets found a non-significant association between short TL and increased 
cancer risk (Shen, Terry et al. 2007). In contrast, in newly diagnosed women with 
spontaneous breast tumors, cancer risk increased with increasing TL (Svenson, Nordfjall et 
al. 2008). Hence, the majority of studies have found blood TL alterations in cancer patients 
when compared to healthy controls. It might be that the type of TL alteration differs 
depending on the tumor type. Differences in the methodology of measuring TL might also 
contribute to the discrepancy. In addition, the type of blood cells that are analyzed can vary 
between different studies.  
The biological mechanisms behind the reported association between blood TL alterations 
and increased cancer risk are not clear. It is not evident whether the TL alterations observed 
in peripheral blood reflect a secondary event caused by the cancer disease, or if the 
alterations are in fact part of the cancer etiology, or both. Oxidative stress has been 
associated with tissue aging, as well as telomere shortening, and it has been proposed that 
the cumulative burden of oxidative stress through life is registered in the telomeres of 
leukocytes (von Zglinicki 2002; Balaban, Nemoto et al. 2005). Accordingly, it has been 
speculated that blood TL may act as a surrogate marker of tissue dysfunctions. In 2003, Wu 
et al. measured TL in peripheral lymphocytes and found an association between short TL 
and increased risk of bladder, head and neck, lung and renal cell cancers (Wu, Amos et al. 
2003). The authors proposed telomere dysfunction as a potential predisposition factor for 
cancer development. It cannot be excluded that the disease itself, or responses to the disease, 
can originate a systemic effect which directly or indirectly affects the telomere length of 
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peripheral blood cells. The immune response to the tumor might need to be considered. 
Some inflammatory molecules, such as cytokines and reactive oxygen species, may have an 
impact on leukocyte TL. A number of cytokines have shown potential to activate telomerase, 
whereas oxidative stress, as mentioned above, might increase telomere attrition (Akiyama, 
Hideshima et al. 2002; von Zglinicki 2002). The proliferation rate of immune cells, and hence 
the telomere attrition rate, may also differ depending of the state of the immune system, 
which in turn might be altered due to the presence of a tumor. 
It was previously reported that the inter-individual TL variation was reduced in the healthy 
aged individuals (≥85 years) (Halaschek-Wiener, Vulto et al. 2008). The authors had 
hypothesized that healthy old individuals without age-related diseases, such as cancer or 
cardiovascular disease, would have unusually long telomeres. The study, however, showed 
that telomere length in the “normal range” may be most protective against tumor 
development, since long telomeres may favor escape from senescence, whereas short TL 
may cause genomic instability. 
Studies investigating blood telomere length as a prognostic indicator in malignancies are 
sparse (Svenson, Ljungberg et al. 2009; Svenson and Roos 2009; Willeit, Willeit et al. 2010).  
A recent prospective, population-based study estimated the impact of peripheral blood 
leukocyte telomere length on overall cancer manifestation and mortality (Willeit, Willeit et 
al. 2010). This study demonstrated significant inverse correlations between baseline 
leukocyte telomere length and both cancer incidence and mortality, which emerged as 
independent of standard cancer risk factors. The authors found evidence of heterogeneous 
effects according to cancer type, whereby tumors with a high fatality rate tended to exhibit 
more prominent relationships with telomere length and tumors with a more favorable 
prognosis showed modest or no associations. These results corroborate  with previous 
evaluations demonstrating a link between short telomere length and lung cancer, bladder 
cancer, renal cell carcinoma, non-Hodgkin lymphoma and head and neck tumors (Wu, 
Amos et al. 2003; Broberg, Bjork et al. 2005; McGrath, Wong et al. 2007; Shao, Wood et al. 
2007; Jang, Choi et al. 2008; Lan, Cawthon et al. 2009),  but failed to obtain significant 
correlations between short telomere length and colorectal and breast cancer (De Vivo, 
Prescott et al. 2009; Shen, Gammon et al. 2009; Zee, Castonguay et al. 2009). A variety of 
experimental and genetic studies support the hypothesis that telomere attrition contributes 
to the manifestation and dissemination of malignancies. While fully functional telomeres 
confer protection of the genome, shortened telomeres facilitate chromosomal instability 
(Calado and Young 2009). 
In fibroblast cultures, accruing senescent cells were shown to produce and release high 
amounts of growth factors, causing an overwhelming proliferation of the surrounding tissue 
and to secrete metalloproteinase, diminishing intercellular adhesions and potentially 
favoring metastatic spread of tumors (Krtolica, Parrinello et al. 2001; Liu and Hornsby 2007). 
Moreover, a significantly higher production of vascular endothelial growth factor in 
senescent cells may stimulate tumor growth and dissemination by promoting 
neovascularization (Coppe, Kauser et al. 2006). The association between short leukocyte 
telomere length and cancer formation may be partially mediated by the aging of the 
immune system itself. Aging of leukocytes reflected by short telomere length may impair 
immune surveillance and reduce the clearance of tumor cells.  
A study demonstrated that patients with multiple myeloma with high telomerase activity 
and short telomere length presented a poor prognosis (Wu, Orme et al. 2003). Accordingly, 
another study reports the same results in adult T-cell leukemia, suggesting that telomerase 
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activity and low telomere content may be novel markers for the prognosis of these diseases 
(Kubuki, Suzuki et al. 2005). 
5.2 Telomerase genetic variants 
In recent years, a growing number of studies have focused on genetic polymorphisms 
influencing cancer risk and prognosis (Araujo, Ribeiro et al. 2007; Nogal, Coelho et al. 2007; 
Teixeira, Ribeiro et al. 2009; Nogueira, Catarino et al. 2010). 
Although telomere shortening is inversely associated with age, telomere length has been 
found to vary considerably in human peripheral blood lymphocytes from individuals of the 
same age (Graakjaer, Pascoe et al. 2004; Londono-Vallejo 2004).  
Rafnar et al (Rafnar, Sulem et al. 2009) demonstrated that polymorphisms in the gene 
encoding TERT, the catalytic subunit of telomerase, were associated with an increased risk 
for cancer of the lung, urinary bladder, prostate and cervix.  
Matsubara and colleagues (Matsubara, Murata et al. 2006) screened the promoter region of 
hTERT for functional polymorphisms and a frequent T to C transition was found 1327 bp 
upstream the transcription starting site (-1327T/C). Individuals homozygous for the -
1327C/C genotype showed lower telomerase activity and shorter telomere length in their 
peripheral leukocytes compared to the -1327T/T and -1327T/C genotypes. 
Matsubara and co-workers (Matsubara, Murata et al. 2006; Matsubara, Murata et al. 2006) 
demonstrated that the -1327T/C polymorphism within the hTERT promoter region has 
functional roles: the -1327T sequence is associated with higher transcriptional activity, lack 
of age-dependent telomere shortening, longer telomere length, and telomerase activity. The 
relationship of the -1327T/C polymorphism to telomere shortening, telomere length, and 
telomerase activity was found in normal peripheral leukocytes. Transcriptional regulation of 
hTERT has a key role in telomerase activity and telomere shortening. Approximately 25% 
higher promoter activity in the -1327T-sequence was found compared the -1327C-sequence 
and the T allele was strongly associated with longer telomere length. Thus, hTERT T allele 
with higher hTERT transcriptional activity is associated with more effective extension of the 
telomeric end during cell division. Another study found an overrepresentation of the -
1327C/C genotype in patients with coronary artery disease compared to controls, 
presenting shorter telomeres compared to other patients with alternative genotypes, 
indicating that a subgroup of patients is more prone to telomere shortening (Matsubara, 
Murata et al. 2006). 
A previous study performed by our group indicates an influence of the telomerase genetic 
variants in overall survival of NSCLC patients. Multivariate Cox regression analysis 
indicated an increased overall survival for T carrier patients, when compared with CC 
genotype, after adjustment for tumor histological type, stage, smoking status, age and 
gender (hazard ratio, HR=0.52). The median estimated cumulative survival was 
significantly higher in T carrier patients, of 26.5 months, comparing with CC patients, of 19.3 
months (Catarino, Araujo et al. 2010). 
Tumors with excessive telomere alterations are therefore likely to possess the most extensive 
phenotypic variability and have the greatest probability of containing cells capable of 
invasion, extravasation and metastasis, i.e., an aggressive tumor phenotype. It has been 
hypothesized that altered telomere length could predispose cells to gain the necessary 
properties to metastasize and cause recurrent disease, and thereby be a predictor of clinical 
outcome (Bisoffi, Heaphy et al. 2006; Willeit, Willeit et al. 2010). 
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6. Concluding remarks 
Cancer remains an important public health problem in developed countries. Therapeutic 
failure and side effects of anticancer therapy are essential issues requiring future research. 
One of the main aims of clinical or translational research in cancer is the search for genetic 
factors that could foresee treatment outcomes, in biologic activity and toxic effects. 
Therefore, the study of tumor and patient genetic profiles, relative to drug-related genes, 
may offer new opportunities for tailoring treatments. 
The assessment of telomere length and telomerase genetic variants could supplement 
prognosis of survival in the course of cancer and may be a promising molecular marker of 
treatment response in cancer patients. Furthermore, a better knowledge of the underlying 
molecular profile of the host and the tumor could facilitate screening for cancer 
susceptibility and tailoring of chemotherapy in individual patients, choosing those most 
likely to respond, adjusting doses more precisely in order to reduce adverse effects, and 
establishing safety profiles based on individual genetic analyses. 
Most cancer cells have strong telomerase activity to maintain telomere lengths for long-term 
cell proliferation. It has been proposed that cancer cells can be killed by inducing critical 
shortening of telomeres, and hence senescence or apoptosis, through inhibition of 
telomerase.  
In most cancers (80%) unlimited replicative potential is achieved through telomerase 
reactivation, allowing telomere lengthening. This major feature of cancer cell biology is 
observed from the earliest stages in most tissues. Early telomerase activation gives a clear 
advantage to established tumor cells, but also contributes to cancer development. Moreover, 
the role of telomeres in carcinogenesis could partly underlie individual, tissue-specific 
predisposition. Indeed, telomere length varies between individuals in the population; some 
studies suggest that hereditary factors are involved in determining telomere length. Thus, 
individual telomere length heterogeneity and telomere-driven instability may be central 
events in early carcinogenesis. 
Overall, these observations highlight the need for improved understanding of telomere-
driven senescence and of the mechanisms involved in the failure of this process to protect 
against cancer progression in the early stages of disease onset. In particular, improved 
understanding of the role and mechanism of action of telomerase in preneoplasia and 
established tumors is essential for current and future developments of accurate and 
individually adapted anti-telomerase anti-cancer therapy. Thus, improvement of the 
methods used to measure telomerase expression and activity will be required. Finally, a 
combination of techniques – each one adapted for studying telomerase, telomere associated 
proteins, DNA damage proteins and telomere length and structure – will be necessary for 
use in future studies, to fully elucidate the molecular mechanisms underpinning telomere-
related biology. 
A possible prognostic impact of TL abnormalities seems to be tumor type dependent and 
more data on well characterized tumor materials are required. It is evident that the 
appearance of a malignancy affects the whole body, and it is possible that the alterations in 
blood TL seen at diagnosis reflect responses to the tumor. Of most interest is perhaps the 
fact that blood TL appears to constitute a significant prognostic indicator, but additional 
studies on different patient cohorts are needed in order to further substantiate this 
indication. Large longitudinal studies and improved standardized protocols are needed for 
the future, to fully be able to evaluate TL as a marker in malignancies. 
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New discoveries pertaining to telomere structure and telomere homeostasis that shed light 
on the complex relationship between telomeres, telomerase, chromosomal instability and 
cancer will undoubtedly have an important impact in cancer therapeutics. 
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